Literature DB >> 1989655

LHRH analogues in breast cancer: clever, but do we need them?

I E Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1989655      PMCID： PMC1971625          DOI： 10.1038/bjc.1991.6

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  15 in total

1.  Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist.

Authors:  W R Miller; W N Scott; R Morris; H M Fraser; R M Sharpe
Journal:  Nature       Date:  1985 Jan 17-23       Impact factor: 49.962

2.  A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer.

Authors:  R B Buchanan; R W Blamey; K R Durrant; A Howell; A G Paterson; P E Preece; D C Smith; C J Williams; R G Wilson
Journal:  J Clin Oncol       Date:  1986-09       Impact factor: 44.544

3.  The treatment of postmenopausal women with advanced breast cancer with buserelin.

Authors:  J H Waxman; S J Harland; R C Coombes; P F Wrigley; J S Malpas; T Powles; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer.

Authors:  H A Harvey; A Lipton; D T Max; H G Pearlman; R Diaz-Perches; J de la Garza
Journal:  J Clin Oncol       Date:  1985-08       Impact factor: 44.544

5.  Gonadotropin-releasing hormone binding sites in human breast carcinoma.

Authors:  K A Eidne; C A Flanagan; R P Millar
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

6.  Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.

Authors:  M Kaufmann; W Jonat; U Kleeberg; W Eiermann; F Jänicke; J Hilfrich; R Kreienberg; M Albrecht; H K Weitzel; H Schmid
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

7.  Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.

Authors:  I L Crighton; M Dowsett; A Lal; A Man; I E Smith
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

8.  Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.

Authors:  A L Harris; J Carmichael; B M Cantwell; M Dowsett
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

9.  Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.

Authors:  P N Plowman; R I Nicholson; K J Walker
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640

10.  Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.

Authors:  R I Nicholson; P V Maynard
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640
View more
  2 in total

1.  Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer.

Authors:  M C Goyette; K Cho; C L Fasching; D B Levy; K W Kinzler; C Paraskeva; B Vogelstein; E J Stanbridge
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

2.  LHRH analogues and breast cancer.

Authors:  E Korkut; A M Comaru-Schally; A V Schally; P N Plowman
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.